Robert L. Redner, MD
Specialist
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 175
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
PA license MD045849L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC Altoona Altoona, PA
- Trinity Medical Ctr East &trinity Medical Ctr West Steubenville, OH
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
- Oncology Hematology Association Inc (202 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 175
- Services billed
- 673
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 357 | 69 |
| Established patient office or other outpatient visit, 40-54 minutes | 152 | 66 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 37 | 36 |
| Hospital discharge day management, more than 30 minutes | 36 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Pittsburgh, PA | 38 |
| Brukinsa (zanubrutinib) | 24 |
| Allopurinol Other prescribers in Pittsburgh, PA | 23 |
| Hydroxyurea Other prescribers in Pittsburgh, PA | 23 |
| Imatinib Mesylate | 17 |
| Ninlaro (ixazomib citrate) | 13 |
| Calquence (acalabrutinib maleate) | 13 |
| Imbruvica (ibrutinib) | 12 |
| Folic Acid Other prescribers in Pittsburgh, PA | 11 |
| Levofloxacin Other prescribers in Pittsburgh, PA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 16 payments worth $1,611 in total to this clinician.
| AbbVie Inc. | $443 |
|---|---|
| Daiichi Sankyo Inc. | $284 |
| E.r. Squibb & Sons, L.l.c. | $226 |
| AstraZeneca Pharmaceuticals LP | $212 |
| Syndax Pharmaceuticals, Inc. | $127 |
| Geron Corporation | $123 |
| Adc Therapeutics America, Inc. | $103 |
| Incyte Corporation | $94.07 |
| Food and Beverage | $1,611 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $13,875 in research payments for these studies, mostly to the institutions running them.
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Takeda Pharmaceuticals U.S.A., Inc. · Recruiting · NCT04419649 - A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.